CN114222740A - 新型极光激酶抑制剂及其用途 - Google Patents

新型极光激酶抑制剂及其用途 Download PDF

Info

Publication number
CN114222740A
CN114222740A CN202080056887.XA CN202080056887A CN114222740A CN 114222740 A CN114222740 A CN 114222740A CN 202080056887 A CN202080056887 A CN 202080056887A CN 114222740 A CN114222740 A CN 114222740A
Authority
CN
China
Prior art keywords
compound
alkyl
pharmaceutically acceptable
formula
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080056887.XA
Other languages
English (en)
Inventor
谢雨礼
樊后兴
钱立晖
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wigen Biomedicine Technology Shanghai Co Ltd
Original Assignee
Wigen Biomedicine Technology Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wigen Biomedicine Technology Shanghai Co Ltd filed Critical Wigen Biomedicine Technology Shanghai Co Ltd
Publication of CN114222740A publication Critical patent/CN114222740A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

本发明公开了一类新型吡啶类化合物及其制备方法和用途。具体地，本发明公开了式(1)所示的化合物及其制备方法，以及式(1)化合物及其药学上可接受的盐或酯作为极光激酶(Aurora Kinase)抑制剂在抗肿瘤药物制备中的用途。

Description

PCT国内申请，说明书已公开。

Claims (8)

  1. PCT国内申请，权利要求书已公开。
CN202080056887.XA 2019-12-03 2020-12-02 新型极光激酶抑制剂及其用途 Pending CN114222740A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201911256773.5A CN112898292A (zh) 2019-12-03 2019-12-03 新型极光激酶抑制剂及其用途
CN2019112567735 2019-12-03
PCT/CN2020/133235 WO2021110009A1 (zh) 2019-12-03 2020-12-02 新型极光激酶抑制剂及其用途

Publications (1)

Publication Number Publication Date
CN114222740A true CN114222740A (zh) 2022-03-22

Family

ID=76110851

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201911256773.5A Pending CN112898292A (zh) 2019-12-03 2019-12-03 新型极光激酶抑制剂及其用途
CN202080056887.XA Pending CN114222740A (zh) 2019-12-03 2020-12-02 新型极光激酶抑制剂及其用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201911256773.5A Pending CN112898292A (zh) 2019-12-03 2019-12-03 新型极光激酶抑制剂及其用途

Country Status (10)

Country Link
US (1) US20220324857A1 (zh)
EP (1) EP4289839A1 (zh)
JP (1) JP2023505239A (zh)
KR (1) KR20220108070A (zh)
CN (2) CN112898292A (zh)
AU (1) AU2020396753A1 (zh)
BR (1) BR112022008717A2 (zh)
CA (1) CA3160577A1 (zh)
MX (1) MX2022006608A (zh)
WO (1) WO2021110009A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI785474B (zh) * 2020-01-22 2022-12-01 大陸商北京加科思新藥研發有限公司 用作選擇性Aurora A抑制劑的新型雜環化合物

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101103017A (zh) * 2004-10-29 2008-01-09 万有制药株式会社 具有Aurora-A选择性抑制作用的新型氨基吡啶衍生物
WO2008026768A1 (en) * 2006-08-31 2008-03-06 Banyu Pharmaceutical Co., Ltd Novel aminopyridine derivatives having aurora a selective inhibitory action
CN101405282A (zh) * 2006-01-23 2009-04-08 安姆根有限公司 极光激酶调节剂和使用方法
WO2009104802A1 (en) * 2008-02-22 2009-08-27 Banyu Pharmaceutical Co., Ltd. Novel aminopyridine derivatives having aurora a selective inhibitory action
CN104159893A (zh) * 2012-02-29 2014-11-19 大鹏药品工业株式会社 新型哌啶化合物或其盐
CN107108567A (zh) * 2014-11-14 2017-08-29 伊莱利利公司 极光激酶a抑制剂

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017294969B2 (en) * 2016-07-13 2021-03-25 Leo Pharma A/S Heteroaromatic modulators of the retinoid-related orphan receptor gamma

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101103017A (zh) * 2004-10-29 2008-01-09 万有制药株式会社 具有Aurora-A选择性抑制作用的新型氨基吡啶衍生物
CN101405282A (zh) * 2006-01-23 2009-04-08 安姆根有限公司 极光激酶调节剂和使用方法
WO2008026768A1 (en) * 2006-08-31 2008-03-06 Banyu Pharmaceutical Co., Ltd Novel aminopyridine derivatives having aurora a selective inhibitory action
WO2009104802A1 (en) * 2008-02-22 2009-08-27 Banyu Pharmaceutical Co., Ltd. Novel aminopyridine derivatives having aurora a selective inhibitory action
CN104159893A (zh) * 2012-02-29 2014-11-19 大鹏药品工业株式会社 新型哌啶化合物或其盐
CN107108567A (zh) * 2014-11-14 2017-08-29 伊莱利利公司 极光激酶a抑制剂

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NATALYA I. VASILEVICH等: "General Ser/Thr Kinases Pharmacophore Approach for Selective Kinase Inhibitors Search as Exemplified by Design of Potent and Selective Aurora A Inhibitors", CHEM BIOL DRUG DES, vol. 88, no. 1, pages 54 - 65, XP055598572, DOI: 10.1111/cbdd.12733 *

Also Published As

Publication number Publication date
KR20220108070A (ko) 2022-08-02
CA3160577A1 (en) 2021-06-10
WO2021110009A1 (zh) 2021-06-10
CN112898292A (zh) 2021-06-04
AU2020396753A1 (en) 2022-06-09
BR112022008717A2 (pt) 2022-07-26
EP4289839A1 (en) 2023-12-13
US20220324857A1 (en) 2022-10-13
JP2023505239A (ja) 2023-02-08
MX2022006608A (es) 2022-07-05

Similar Documents

Publication Publication Date Title
CN113563323B (zh) 一类苯并噻唑基联芳基类化合物、制备方法和用途
US20230118795A1 (en) Aryl or heteroaryl pyridone or pyrimidine derivative, preparation method and use thereof
CN106749233B (zh) 一类磺酰胺衍生物及其应用
EP3119760A1 (en) Piperidine-dione derivatives
CN114269735A (zh) 二氢或四氢喹唑啉类化合物及其中间体、制备方法和应用
EA035499B1 (ru) Новые ингибиторы глутаминазы
RU2692479C2 (ru) (5,6-дигидро)пиримидо[4,5-е]индолизины
CN114423751B (zh) 用作选择性aurora a抑制剂的新型杂环化合物
JP2021512055A (ja) Ｔａｍファミリーキナーゼ／及びｃｓｆ１ｒキナーゼ阻害剤及びその用途
CN118055933A (zh) 选择性parp1抑制剂及其应用
KR20220007111A (ko) 키나아제 억제제로 사용되는 화합물 및 이의 응용
CN114072400B (zh) 极光激酶抑制剂及其用途
EP4105207A1 (en) Quinolyl phosphine oxide compound, and composition and application thereof
CN114222740A (zh) 新型极光激酶抑制剂及其用途
CA3093323A1 (en) Oxazino-quinazoline and oxazino-quinoline type compound, preparation method and uses thereof
AU2021300495B2 (en) Aryl phosphorus oxide compounds and use thereof
WO2021240424A1 (en) Indazole and benzoisoxazole dihydroorotate dehydrogenase inhibitors
CN115867542A (zh) 新型苯并咪唑化合物
EA045833B1 (ru) Соединение, используемое как ингибитор киназы, и его применение
CN116514728A (zh) 一种喹唑啉衍生物及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination